Investors Aren't Buying Ercros, S.A.'s (BME:ECR) Earnings

With a price-to-earnings (or "P/E") ratio of 8.2x Ercros, S.A. (BME:ECR) may be sending very bullish signals at the moment, given that almost half of all companies in Spain have P/E ratios greater than 19x and even P/E's higher than 43x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so limited.

There hasn't been much to differentiate Ercros' and the market's retreating earnings lately. One possibility is that the P/E is low because investors think the company's earnings may begin to slide even faster. You'd much rather the company wasn't bleeding earnings if you still believe in the business. At the very least, you'd be hoping that earnings don't fall off a cliff if your plan is to pick up some stock while it's out of favour.

Check out our latest analysis for Ercros

pe
BME:ECR Price Based on Past Earnings September 11th 2020
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Ercros.
Advertisement

Is There Any Growth For Ercros?

There's an inherent assumption that a company should far underperform the market for P/E ratios like Ercros' to be considered reasonable.

If we review the last year of earnings, dishearteningly the company's profits fell to the tune of 5.1%. As a result, earnings from three years ago have also fallen 46% overall. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.

Shifting to the future, estimates from the one analyst covering the company suggest earnings should grow by 0.2% per annum over the next three years. That's shaping up to be materially lower than the 13% each year growth forecast for the broader market.

In light of this, it's understandable that Ercros' P/E sits below the majority of other companies. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.

The Key Takeaway

Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

We've established that Ercros maintains its low P/E on the weakness of its forecast growth being lower than the wider market, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

You always need to take note of risks, for example - Ercros has 4 warning signs we think you should be aware of.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with a strong growth track record, trading on a P/E below 20x.

When trading Ercros or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Valuation is complex, but we're here to simplify it.

Discover if Ercros might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

About BME:ECR

Ercros

Manufactures and sells chemical and pharmaceutical products in Spain and internationally.

Fair value with imperfect balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1158.7% undervalued
32 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.6% undervalued
49 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9220.2% undervalued
15 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1908.3% undervalued
11 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative

Updated Narratives

AV
IOT logo
Averagemike on Samsara ·

Samsara's Future PE Will Soar to 337.7x and the Future is Bright

Fair Value:US$57.34k99.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
JO
John_Eric
NOW logo
John_Eric on ServiceNow ·

The Company Nobody Brags About

Fair Value:US$266.0164.1% undervalued
30 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
A176750 logo
AnimalDoctorKwon on DuChemBIOLtd ·

DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.

Fair Value:₩10k43.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75029.1% undervalued
102 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6514.6% undervalued
69 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
BL
BlackGoat
CBRS logo
BlackGoat on Cerebras Systems ·

The Wafer Giant Threatening NVIDIA's GPU Hegemony

Fair Value:US$415.5449.5% undervalued
64 users have followed this narrative
3 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

ST
StoxEurope
AD logo
StoxEurope on Koninklijke Ahold Delhaize ·

I ran Ahold Delhaize through a three-model triangulation — DCF, dividend discount, and residual income — with every assumption published and tagged as fact or assumption. The interesting result isn't a number, it's a disagreement: the point estimates run from €20,03 (RIM) through €27,64 (DDM) to €64,91 (DCF), and the pairwise overlaps form two disjoint segments — €20,36–€21,54 and €39,60–€44,56. Between €21,54 and €39,60, no two of the three models agree. [img]https://staticm.fastcomments.com/1784197249786-1000x1000-ad-range-strip.png[/img] Most of the spread is lens properties rather than company drama. A dividend model structurally can't see the roughly half of shareholder returns Ahold pays through buybacks. The book is ~96 % goodwill from the 2016 merger, which pins the residual-income reading low. And ~83 % of the DCF's value sits beyond the explicit five years, so it leans hard on the terminal assumptions. Three honest lenses, three honest answers — the disagreement is the information. Disclosures Position disclosure: The author holds no position in Ahold Delhaize as at 9 July 2026. This valuation is a StoxEurope opinion, based on honest research. Mistakes are possible. This is not investment advice. Do your own research. This article demonstrates a valuation methodology. It is not an investment recommendation, is not personalised to any reader's circumstances, and every figure in it depends entirely on the stated assumptions

1
|
0